US blood pressure drug recall does not affect Singapore: HSA

Health Sciences Authority (HSA)

Published Nov 05, 2026, 06:10 PM

Updated Nov 05, 2026, 06:10 PM

HSA said the US recall of Macleods’ blood pressure drug does not affect Singapore because the affected products are not sold here.

The recall covers Tribenzor tablets from two lots after “failed dissolution specifications” raised concerns the medicine may not work properly.

The US FDA made it a Class II recall, meaning possible “temporary or medically reversible adverse health consequences”, but serious harm is unlikely.

SINGAPORE - A recent recall which resulted in more than 3,700 bottles of blood pressure medicine taken off the shelves in the United States does not affect consumers here, said the Health Sciences Authority (HSA).

Macleods Pharmaceuticals announced in early October that it is recalling certain batches of olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets, sold under the brand name Tribenzor as a medication for hypertension, or high blood pressure.

“The affected products manufactured by Macleods Pharmaceuticals are not marketed in Singapore,” said HSA in response to queries from The Straits Times.

“Hence, the product recall in the US does not affect medicines supplied through authorised local distribution channels here.”

The reason given for the recall was “failed dissolution specifications” – that is, the pills did not dissolve as required and as such may not be effective.

The recall covers 3,528 bottles containing 30 tablets and 216 bottles with 90 tablets – from lot 12251163A and lot 12251163B respectively – which expire on May 31, 2027.

On Oct 26 the US Food and Drug Administration classified the recall as Class II, meaning use of the affected medication could cause “temporary or medically reversible adverse health consequences” but is unlikely to cause serious health consequences.

Under a Class II recall, consumers can generally continue taking the medication unless advised otherwise.

Health Sciences Authority

卫生科学局（HSA）

发布于2026年11月5日下午6:10

更新于2026年11月5日下午6:10

新加坡卫生科学局表示，美国召回麦克劳德公司生产的降血压药不会影响新加坡，因为受影响的产品并未在新加坡销售。

此次召回涉及两批次的Tribenzor片剂，原因是“溶解度指标不达标”引发了人们对该药物可能无法正常发挥作用的担忧。

美国食品药品监督管理局将其列为 II 类召回，这意味着可能存在“暂时性或医学上可逆的不良健康后果”，但不太可能造成严重伤害。

新加坡——新加坡卫生科学局（HSA）表示，最近美国召回的3700多瓶降压药不会影响新加坡的消费者。

Macleods Pharmaceuticals 于 10 月初宣布，将召回某些批次的奥美沙坦酯、氨氯地平和氢氯噻嗪片，这些药物以 Tribenzor 的品牌名销售，用于治疗高血压。

新加坡卫生科学局在回复《海峡时报》的询问时表示：“受影响的麦克劳德制药公司生产的产品并未在新加坡销售。”

“因此，美国的产品召回不会影响通过本地授权分销渠道供应的药品。”

召回的原因是“未达到溶解度标准”——也就是说，药片没有按要求溶解，因此可能无效。

此次召回涉及批号分别为 12251163A 和 12251163B 的 3,528 瓶 30 片装药片和 216 瓶 90 片装药片，有效期至 2027 年 5 月 31 日。

10 月 26 日，美国食品药品监督管理局将此次召回定为 II 类召回，这意味着使用受影响的药物可能会导致“暂时的或医学上可逆的不良健康后果”，但不太可能导致严重的健康后果。

根据 II 类召回规定，除非另有医嘱，消费者一般可以继续服用该药物。

健康科学管理局